Lupine shares jump more than 3% on plans to invest $250 million for new U.S. facility

Shares of drugmaker Lupine Ltd. gained more than 3% on Thursday, October 9, after the company announced plans to establish an advanced pharmaceutical manufacturing facility in Coral Springs, Florida, in an effort to improve U.S. production of critical respiratory medications.

The facility represents a strategic step to strengthen medication safety and support the health of Florida families and the American population at large.

The project involves a cumulative investment of $250 million over five years, covering research and development, infrastructure and capital expenditure.

The new factory will have the capacity to produce more than 25 essential respiratory medicines, including life-saving albuterol inhalers for asthmatic children and military personnel, both at home and abroad.

By boosting domestic manufacturing and diversifying the supply chain, Lupine aims to strengthen its position as a global leader in respiratory medicines. The initiative is also expected to generate more than 200 long-term skilled jobs in Broward County by 2030, boosting the local economy.

Previously, US President Donald Trump imposed 100% tariffs on branded and patented drugs, but these duties would be waived if companies have manufacturing plants in the United States.

Also Read: Lupine Receives OAI Classification from USFDA for Pithampur Unit 2 Manufacturing Plant

Christoph Funke, Lupin’s Director of Technical Operations, said, “Expanding Lupine’s footprint in Coral Springs is a critical part of our growth strategy. This new state-of-the-art facility will build on our existing presence in Florida, home to Lupine’s corporate headquarters and our Advanced Inhalation Research Center.

The Coral Springs facility will anchor U.S. production of critical respiratory therapies, diversify the supply chain, and ensure affordable and reliable access, from routine pediatric care to pandemic-scale demand. Lupine acquired more than 5 acres of land to embark on this 70,000 square foot expansion.

In recognition of its investment and job creation projects, Lupine will receive tax credits and incentives from the State of Florida. Lupine is partnering with Florida Commerce/Select Florida, the City of Coral Springs, the Greater Fort Lauderdale Alliance and the Broward County Commission (Workforce/University partner) on this strategic project.

Also read: Lupine launches blood sugar control injection in the US

Shares of Lupine were trading 3.4% higher on Thursday at ₹1,970.2. The stock has underperformed so far in 2025, with losses of 17%.